JAK selectivity: more precision less troubles

Giulia Roda, Arianna Dal Buono, Marjorie Argollo, Silvio Danese

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Janus kinases inhibitors (JAKi) are new small molecules recently introduced in the armamentarium of treatments for Inflammatory Bowel Disease (IBD). Janus Kinases (JAK) are tyrosine kinases that act by linkage with different intracellular receptors, regulating cytokines gene transcription implicated in the inflammatory burden seen in IBD patients.

AREAS COVERED: A comprehensive literature search was performed to retrieve studies on JAKi and IBD to discuss the latest developments and how the selectivity of these drugs is changing the natural course of IBD.

EXPERT OPINION: Available data on efficacy and safety of JAKi in IBD are highly encouraging and because of their selectivity, these drugs might become among the foremost options in the treatment algorithm.

Original languageEnglish
Pages (from-to)789-796
Number of pages8
JournalExpert Review of Gastroenterology and Hepatology
Issue number9
Publication statusPublished - Sep 2020


Dive into the research topics of 'JAK selectivity: more precision less troubles'. Together they form a unique fingerprint.

Cite this